^
    1d
    Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study. (PubMed, Hemasphere)
    Treatment-emergent adverse events (TEAEs) led to treatment discontinuation in 16.0% of patients with CR; the most common TEAE was cytokine release syndrome (56.4%). This generally manageable safety profile and the sustainability of CRs support odronextamab as a potential long-term treatment for heavily pretreated R/R FL.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Ordspono (odronextamab)
    1d
    Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. (PubMed, Pathology)
    Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.
    Journal
    |
    CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    2d
    A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Kyowa Kirin, Inc. | N=34 --> 72
    Enrollment change • Trial initiation date • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive
    2d
    HX009-II-02: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=48, Completed, Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting --> Completed | N=99 --> 48 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HX-009
    2d
    SYMPHONY-1: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (clinicaltrials.gov)
    P3, N=555, Active, not recruiting, Epizyme, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Feb 2027
    Enrollment closed • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    2d
    KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=56, Recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jan 2028 --> Apr 2028 | Trial primary completion date: Jan 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    gemcitabine • lacutamab (IPH4102)
    2d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    4d
    The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma. (PubMed, Int J Cancer)
    Together, our data indicate that ZDHHC11 promotes BL cell growth at least in part by stimulating expression of MEF2B, which promoted BL cell survival through both BCL6-dependent and independent pathways. Our work highlighted the importance of the MEF2B-BCL6 axis, which strongly supports BL growth and identified ZDHHC11 as a novel regulator of this axis.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • ZDHHC11 (Zinc Finger DHHC-Type Containing 11)
    5d
    BHARAT-1: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov)
    P1, N=27, Terminated, Aurigene Discovery Technologies Limited | N=80 --> 27 | Recruiting --> Terminated; Patient recruitment problems.
    Enrollment change • Trial termination • First-in-human
    |
    AUR-103
    5d
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK negative
    |
    cyclophosphamide • vincristine • prednisone • aclarubicin
    5d
    GAZAI: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (clinicaltrials.gov)
    P2, N=89, Completed, Heidelberg University | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab)
    5d
    Study of Tazemetostat in Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=6, Terminated, University of Alabama at Birmingham | N=30 --> 6 | Trial completion date: Dec 2029 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Mar 2026; Ipsen, drug company requested all studies using the drug Taxemetostat be terminated due to increased risk of secondary malignancies in subjects.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tazverik (tazemetostat)